comprehensive -WSS

comprehensive

author：entertainment 2025-09-05 07:00:08 - browse：1373

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Companies helping big Covid

entertainment

WSS

What causes an itch? Researchers may have solved the mystery

Radiology is caught between AI's potential and concern for patients

What PEPFAR has meant on the ground in Ukraine

Women's World Cup brings attention to abuse in soccer

CMS should re

AI models in health care face new federal disclosure requirements

leisure time

comprehensive

leisure time

Walensky prepares to leave CDC — and Congress — behind

AI models in health care face new federal disclosure requirements

DIEP, the 'gold standard' of breast reconstruction, is under threat

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Medical leaders decry Supreme Court decision on affirmative action

Inflation cooled significantly in June, bringing price hikes close to normal levels

Tori Bowie and the unacceptable rates of Black maternal death

Americans' trust in science, scientist continues decline: Report

George Santos makes 1st court appearance after pleading not guilty to 13 counts

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

hotspot

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Why sickle cell disease is getting the first CRISPR treatment

Radiology is caught between AI's potential and concern for patients

Congenital heart disease patients face new threat of heart failure

SCOTUS to consider access to abortion pill mifepristone

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

entertainment

focus

entertainment

Wikipedia